Piper Sandler Lowers Envista (NYSE:NVST) Price Target to $39.00

Posted by on Oct 28th, 2023

Envista (NYSE:NVST – Get Free Report) had its price objective cut by equities researchers at Piper Sandler from $46.00 to $39.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price target indicates a potential upside of 65.82% from the company’s previous close.

A number of other analysts have also recently commented on NVST. Bank of America cut their price target on shares of Envista from $47.00 to $45.00 in a research note on Tuesday, July 11th. Evercore ISI cut their price target on shares of Envista from $40.00 to $30.00 in a research note on Wednesday, October 11th. Finally, Morgan Stanley dropped their price objective on shares of Envista from $46.00 to $42.00 and set an “overweight” rating on the stock in a research report on Friday, October 20th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.80.

Check Out Our Latest Analysis on NVST

Envista Stock Performance

Shares of NVST stock opened at $23.52 on Thursday. The stock has a market cap of $3.85 billion, a P/E ratio of 19.12, a P/E/G ratio of 1.41 and a beta of 1.44. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.29 and a quick ratio of 1.04. The company has a fifty day moving average price of $28.52 and a two-hundred day moving average price of $32.55. Envista has a one year low of $23.17 and a one year high of $43.29.

Envista (NYSE:NVST – Get Free Report) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.02. The firm had revenue of $662.40 million during the quarter, compared to analysts’ expectations of $655.81 million. Envista had a net margin of 8.40% and a return on equity of 7.60%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.48 earnings per share. As a group, equities analysts predict that Envista will post 1.86 EPS for the current year.

Hedge Funds Weigh In On Envista

Several large investors have recently modified their holdings of NVST. Franklin Resources Inc. grew its stake in shares of Envista by 44.7% in the second quarter. Franklin Resources Inc. now owns 5,192,285 shares of the company’s stock valued at $175,707,000 after acquiring an additional 1,603,147 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Envista by 50.5% in the fourth quarter. Alliancebernstein L.P. now owns 4,209,467 shares of the company’s stock valued at $141,733,000 after acquiring an additional 1,412,915 shares in the last quarter. Norges Bank acquired a new position in shares of Envista in the fourth quarter valued at about $32,880,000. Dimensional Fund Advisors LP grew its stake in shares of Envista by 14.6% in the second quarter. Dimensional Fund Advisors LP now owns 6,047,276 shares of the company’s stock valued at $204,640,000 after acquiring an additional 768,687 shares in the last quarter. Finally, Employees Retirement System of Texas acquired a new position in shares of Envista in the second quarter valued at about $24,940,000.

Envista Company Profile

(Get Free Report)

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.

See Also

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.